Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Marcia Macphearson

Partner, Health & Life Sciences, Oliver Wyman

Specialty drugs represent an opportunity to better serve patients, but also pose risks.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Actuarial, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Director, Marsh & McLennan Advantage, Healthcare

Fourteen percent of physicians offer virtual visits. But a new CMS rule may make telehealth more commonplace.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Five success factors for accelerating innovation through strategic partnerships.

Partner, Health & Life Sciences, Oliver Wyman

Today's market requires a new approach to medical cost management. Learn about common pitfalls and five program must-haves.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Two scenarios for how repeal and replace changes might unfold.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

Now is the time -- why insurers must better understand the unique needs of the ACA population.

Partner, Health & Life Sciences, Oliver Wyman

Powerful new consumer tools are shedding light on previously hidden service costs and quality outcomes in healthcare. Yet, a closer look reveals that transparency solutions may have unintended, less-than-favorable consequences for consumers.

Senior Vice President, Health Care Value, BCBSM
Partner, Health & Life Sciences, Oliver Wyman